海創藥業(688302.SH):2024年淨虧損1.98億元
格隆匯2月27日丨海創藥業(688302.SH)公佈2024年度業績快報,報告期內,歸屬於母公司所有者的淨利潤爲-19,804.97萬元,同比減虧9,610.88萬元;歸屬於母公司所有者的扣除非經常性損益的淨利潤爲-21,604.58萬元,同比減虧10,898.38萬元;報告期末,公司總資產136,160.48萬元,同比減少8.71%;歸屬於母公司的所有者權益119,266.31萬元,同比減少12.76%。報告期內,公司尚無藥品獲得商業銷售批準,未產生藥品銷售收入。報告期內材料及研發中間體銷售實現營業收入36.68萬元,上年同期無營業收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.